POPULARITY
88 episodes with genitourinary
16 episodes with genitourinary
20 episodes with genitourinary
9 episodes with genitourinary
8 episodes with genitourinary
4 episodes with genitourinary
7 episodes with genitourinary
7 episodes with genitourinary
5 episodes with genitourinary
4 episodes with genitourinary
4 episodes with genitourinary
6 episodes with genitourinary
4 episodes with genitourinary
2 episodes with genitourinary
2 episodes with genitourinary
3 episodes with genitourinary
7 episodes with genitourinary
5 episodes with genitourinary
From painless hematuria to paraneoplastic syndromes, GU cancers can get overwhelming very quickly. Fortunately, OMS3 Angelica Batholomew from Ohio University Heritage College of Osteopathic Medicine in Cleveland will make this topic much easier!
From painless hematuria to paraneoplastic syndromes, GU cancers can get overwhelming very quickly. Fortunately, OMS3 Angelica Batholomew from Ohio University Heritage College of Osteopathic Medicine in Cleveland will make this topic much easier!
Examine the vulva in menopause consultations Biopsy is important for diagnosis Differentiating vulval conditions Treatment with potent topical steroids Referral considerations The questions answered in this podcast are listed below.They were compiled by GPs and health professionals around Australia who attended Healthed’s face-to-face seminars. Do you always examine the vulva in the menopause consult, or would you wait and see if the patient doesn’t have the expected response to vaginal oestrogen? How do we differentiate between lichen sclerosus, lichen planus, or lichen simplex chronicus? Do you think the itch of lichen sclerosus responds to vaginal oestrogen? Could you give this to a woman, and she’s going to get better, and you’ll never know that she had lichen sclerosus? What treatments do you use, and for how long? Can you take a punch biopsy from one site - the site that you think is perhaps the easiest to biopsy or looks the most affected? Is a 3 mm punch biopsy big enough? Do you have to pop a suture in? How do you manage the care of that biopsy after you’ve done it? Is referring to a dermatologist or gynaecologist better for biopsy? Which steroids do you use, for how long, and what results do you expect? How does a woman present with lichen planus? Host: Dr Marita long | Total Time: 23 mins Expert: Dr Terri Foran, Sexual Health Physician Register for our fortnightly FREE WEBCASTSEvery second Tuesday | 7:00pm-9:00pm AEST Click here to register for the next oneSee omnystudio.com/listener for privacy information.
Today, we cover ASCO 2025 in the genitourinary space, specifically bladder and renal cancer. Dr. Enrique Grande, a renowned oncologist and Program and Clinical Research lead of MD Anderson Cancer Centre, Madrid, joins us. This is a mega episode where we cover AMPLITUDE, JAVELIN MEDLEY, CHECKMATE 901 and NIAGARA, advancing urothelial cancer care; SEAR 02 and the CReST trial, pushing boundaries in bladder cancer; CHECKMATE 214; LITESPARK-005 and LITESPARK-004, showcasing belzutifan's promise; and KEYNOTE-564, adjuvant therapy for kidney cancer. Stay tuned for an insightful conversation on how these trials may be transforming patient outcomes!Studies discussed in the episode:CHECKMATE 901NIAGARACHECKMATE 214CREST trialSEAR 02LITESPARK 004/005AMPLITUDEJAVELIN MEDLEYFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
In this episode, I'm talking about something I see all the time in my practice but that too many women still suffer through in silence: Genitourinary Syndrome of Menopause (GSM). This condition shows up in women as estrogen levels decline, most commonly during and after menopause.If you've been dealing with vaginal dryness, itching, pain with intercourse, or repeated urinary tract infections, you're not alone, and it may be GSM.I walk you through the updated guidelines from the American Urologic Association (AUA) and the American Urogynecologic Society (AUGS) for diagnosing and treating GSM. We talk about what symptoms to look for and the full range of treatment options, including hormonal and non-hormonal therapies, so you can make informed decisions that work for you.In this episode, I also cover:Why follow-up care is just as important as starting treatmentHow shared decision-making with your provider changes outcomesWhat research still needs to catch up when it comes to cost and accessIf you've ever wondered if your symptoms are "just aging" or felt unsure about what's normal after menopause, this episode is for you. My goal is to empower you with information and make sure you know you're not alone.For more information on this study: https://www.auanet.org/guidelines-and-quality/guidelines/genitourinary-syndrome-of-menopauseTimeline:00:30 Introduction to Genital Urinary Syndrome of Menopause 01:25 Understanding the Symptoms and Diagnosis 03:15 Guidelines for Treatment 06:09 Hormonal Treatments and Recommendations 07:43 Non-Hormonal Treatments and Considerations 08:49 Energy-Based Treatments and Their Efficacy 10:36 Cancer Concerns and Hormonal Treatments 13:14 Follow-Up and Long-Term Management 14:04 Conclusion and Future Research
Better Edge : A Northwestern Medicine podcast for physicians
In this episode of Better Edge, we discuss the Collaborative Advanced Reconstructive Evaluation (CARE) Clinic, a collaboration between Northwestern Medicine and Ann & Robert H. Lurie Children's Hospital of Chicago, led by Julia Geynisman-Tan, MD, Julia E. Grabowski, MD, Elizabeth B. Yerkes, MD, and Dana Elborno, MD. Learn how this team uses a multidisciplinary approach to provide leading-edge reconstructive treatments for congenital anomalies and acquired genitourinary tract diseases.
Today, we're joined by Professor Anthony Joshua, head of Medical Oncology at St. Vincent's Hospital, Sydney, and a global leader in prostate cancer and melanoma. In this episode, Professor Joshua discusses multiple trials including AMPLITUDE, advancing prostate cancer therapies; CAN 2409, exploring immunotherapy; ARANOTE, showing darolutamide's impact on progression-free survival; the prognostic significance of PSA 0.2; and the landmark STAMPEDE study. Join us for a deep dive into these game-changing studies. Let's begin! It's a jam-packed episode!Studies discussed in the episode:AMPLITUDECAN2409ARANOTESTAMPEDE*AND MORE!For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
A 65-year-old male with benign prostatic hyperplasia (BPH) reports frequent urination, urgency, and nocturia. Which of the following mechanisms BEST explains these symptoms? Find it all out in the podcast! Be prepared for the NPTE so that you can pass with flying colors! Check out www.ptfinalexam.com/podcast for more information and to stay up-to-date with our latest courses and projects. #Npte #PT #ptboards #crushtheNPTE #study #studygram #spt #ptstudent #ptlife #sptprobs #physicaltherapystudent #physicaltherapy #physio #physiotherapist #ptlife #ptstudentstudy
Our guest is Dr. Irene Crescenze, an Associate Professor of Urology at Ohio State Univeristy. She talks with us about Genitourinary Syndrome of Menopause, or GSM. Learn what you should know about symptoms, treatment and improving your quality of life. For more podcasts, follow The Urology Care Podcast on Spotify, SoundCloud, and/or iTunes. Don't forget to subscribe to our free digital magazine, UrologyHealth extra® at www.urologyhealth.org/uhe. **** May 30, 2025
Vaginal oestrogen is safe at any age, including over 70, with regular review Use vaginal oestrogen cautiously in younger women; rule out other causes such like vulval dermatitis In breast cancer survivors, vaginal oestrogen is off-label; prefer estriol and involve oncology Vaginal DHEA (Intrarosa) is effective with minimal absorption; lacks long-term safety data; no washout needed when switching The questions answered in this podcast are listed below.They were compiled by GPs and health professionals around Australia who attended Healthed’s face-to-face seminars. What are the main symptoms for women with vaginal atrophy, and what is the general approach when a woman comes to talk about these symptoms? How long can women use vaginal oestrogen for? If you saw a woman over the age of 70, would you feel comfortable allowing her to continue using vaginal oestrogen? Is it safe to use vaginal oestrogen in a younger woman who might be breastfeeding or taking the combined oral contraceptive pill and experiencing vaginal dryness or discomfort? Do you need to take the same precautions for side effects as you would with systemic hormone therapy? For example, if there was a woman who was prone to venous thromboembolism (VTE), is it safe for her to use vaginal oestrogen? Is there any role for vaginal oestrogen in reducing the frequency of recurrent genital herpes outbreaks? Are there situations where you would use vaginal oestrogen in combination with a non-hormonal product for better results? Thoughts on laser treatments, microneedling, or PRP for vaginal or vulval symptoms? In women who present with urethral caruncles, is there a role for vaginal oestrogen as part of the treatment? How long would you try using vaginal oestrogen for that? What about the doses of oestrogen when treating someone who's had breast cancer? What do we have to be mindful of? What about women with a history of endometrial, cervical, or vulval cancer? Can we use vaginal oestrogen if they've got symptoms? Can DHEA (Intrarosa) be used safely in women with a history of cancer? For women without breast cancer, when would you use DHEA instead of oestrogen? Would you ever use both oestrogen and DHEA together? What about using DHEA in conjunction with systemic menopausal hormone therapy? Are there any thoughts around the improvements in libido with the use of DHEA? If you had tried someone on Ovestin (estriol) and wanted to switch to Intrarosa, is a washout period required before starting? Host: Dr Marita long | Total Time: 33 mins Expert: Dr Terri Foran, Sexual Health Physician Register for our fortnightly FREE WEBCASTSEvery second Tuesday | 7:00pm-9:00pm AEST Click here to register for the next oneSee omnystudio.com/listener for privacy information.
In this Healthed lecture, A/Prof Gino Pecoraro discusses the prevalence and pathophysiology of this condition as well as providing the latest, evidence based recommendations for its treatment. Importantly, he will also be talking about commonly-advertised therapies that have no evidence of effectiveness, and some that have actually been shown not to work.See omnystudio.com/listener for privacy information.
In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Adriana Herrera, CEO at Pierre Fabre Pharmaceuticals (USA). Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Adriana, covering: Why Big Pharma is such a great training ground for future pharma leaders, and how a period living and working in Mexico defined her leadership style The reality of being purchased by a big pharma like Gilead, and retaining independence as the acquired company, Kite Pharma The opening of a market opportunity that led Adriana to her first CEO role, and how the role is pushing her outside of her comfort zone Why she is optimistic about the future of manufacturing and commercialising cell therapies - innovation will find a way, but it takes time How the current geopolitical environment is adding more risk and uncertainty to an industry plagued with risk... and how that may impact investments and supply chains Adriana leads the expansion of Pierre Fabre's US presence in precision oncology, cell therapy and rare diseases with an immediate focus on the commercialization of a groundbreaking allogenic cell therapy. Most recently, Adriana served as U.S. General Manager at Kite Pharma where she successfully commercialized the autologous CART-cell therapy portfolio and led the US commercial functions. Prior to that, her experience included a tenure at Eisai as Senior Vice President and commercial head for U.S. Oncology and high-impact leadership roles at Novartis Oncology including Vice President and Global Diseases Lead for Lung and Genitourinary cancers. Adriana commenced her career at Bristol Myers-Squibb. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
Developed by the Medical Student Membership Workgroup, the Urology Spotlight Series educates medical students about a particular subspecialty within urology, including common cases and procedures. In this episode, medical student, Jake Ratanawong, is joined by Dr. Sean Elliott, Professor and Director of Reconstructive Urology at the University of Minnesota, for a discussion on the field of Genitourinary Reconstruction.
In 2014, the International Society for the Study of Women's Sexual Health together with the North American Menopause Society introduced the term “Genitourinary syndrome of menopause” to replace the prior term vulvovaginal atrophy. Ten years after that, in 2024, a related term “Genitourinary Syndrome of LACTATION, was introduced to better capture the genitourinary issues lactating women may experience. A new systematic review, soon to be released in the journal obstetrics and gynecology, provides new data on GSL prevalence and characteristics. This is a good reminder for any clinician who evaluates postpartum/lactating women to ask about GSL. How does sexual dysfunction fit into this question? Listen in to the next episode of Dr. Chapa's Clinical Pearls Podcast for more details.
JUST DROPPED! The 2025 Genitourinary Syndrome of Menopause (GSM) guidelines are here — and trust us, they're a game-changer for pelvic health pros. Pelvic pain, dryness, urgency, and more — GSM is so much more than just hot flashes.The 2025 Genitourinary Syndrome of Menopause guidelines just dropped — and they're packed with clinical pearls pelvic health OTs can't afford to miss. What's new? What's outdated? What's YOUR role as an OT?We're breaking it all down in this week's episode of the OTS in Pelvic Health Podcast — and let's just say…you'll never look at menopause the same way again. Listen now. Learn more. Lead better. Link in bio.#PelvicHealthOT #GSM2025 #MenopauseMatters #OccupationalTherapy #WomensHealthOT #PelvicFloorTherapy #GSMguidelines #TraumaInformedOT #OTpodcast_______________________________________________________________Podcast: OTs in Pelvic HealthOT Pelvic Health HeadQuarters____________________________________________________________________________________________Pelvic OTPs United - Lindsey's off-line interactive community for $39 a month! Inside Pelvic OTPs United you'll find: Weekly group mentoring calls with Lindsey. She's doing this exclusively inside this community. These aren't your boring old Zoom calls where she is a talking head. We interact, we coach, we learn from each other. Highly curated forums. The worst is when you post a question on FB just to have it drowned out with 10 other questions that follow it. So, she's got dedicated forums on different populations, different diagnosis, different topics (including business). Hop it, post your specific question, and get the expert advice you need. More info here. Lindsey would love support you in this quiet corner off social media!
In this episode of the Sky Women's Health Podcast, Dr. Carolyn Moyers, board-certified OB/GYN and Menopause Society Certified Provider, breaks down the newly released 2024 American Urological Association (AUA) Clinical Guideline on Genitourinary Syndrome of Menopause (GSM).
Video: https://mehlmanmedical.com/hy-usmle-q-1375-repro-genitourinaryIG: https://www.instagram.com/mehlman_medical/Telegram: https://mehlmanmedical.com/subscribe/FB: https://www.facebook.com/mehlmanmedical
In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Joan Carles, Head of Section for the Genitourinary, Central Nervous System, Sarcomas and Tumours of Unknown Origin Unit at Vall d'Hebron University Hospital. Carles discusses breakthroughs in genitourinary cancer and sarcoma treatment, including anti-angiogenic therapies, overcoming resistance, and the role of genetic polymorphisms in personalised medicine. Timestamps: 00:00 – Introduction 01:56 – Anti-angiogenic therapies 05:03 – Treatment resistance 07:53 – Genetic polymorphisms 09:02 – Sarcoma treatments 11:16 – Novel drugs 15:22 – Oncology societies 18:00 – Carles' three wishes for healthcare
In this episode, Catherine Fahey, MD, PhD; Alexandra Leary, MD, PhD; Funda Meric-Bernstam, MD; and Zev A. Wainberg, MD, explore the mechanisms of HER2-targeted antibody–drug conjugates (ADCs) and emerging clinical data with these agents across genitourinary, gastrointestinal, and gynecologic cancers.Mechanisms of action of ADCs: how ADCs selectively deliver potent chemotherapy to tumor cellsClinical data across tumor types: highlights from recent trials with trastuzumab deruxtecan and exploration of emerging data on agents such as disitamab vedotinChallenges and future directions:key considerations for combining HER2-targeted ADCs with immunotherapy or chemotherapy, and sequencing ADC therapiesPresenters:Catherine Fahey, MD, PhDAssistant ProfessorDivision of OncologyUniversity of North Carolina at Chapel HillChapel Hill, North CarolinaAlexandra Leary, MD, PhDPresident, GINECO GroupCo-Director, Department of Medical OncologyMedical Oncologist GynecologyTeam Leader, Gynecologic Translational Research Lab, INSERM u981Institut Gustave RoussyVillejuif, FranceFunda Meric-Bernstam, MDChair, Department of Investigational Cancer TherapeuticsMedical Director, Institute for Personalized Cancer TherapyNellie B. Connally Chair in Breast CancerThe University of Texas MD Anderson Cancer CenterHouston, TexasZev A. Wainberg, MDProfessor of Medicine and SurgeryCo-Director of GI OncologyDirector, Early Phase Clinical Research ProgramJonsson Comprehensive Cancer CenterUCLA School of MedicineLos Angeles, CaliforniaLink to full program:https://bit.ly/42iEDjVTo claim credit for listening to this episode, please visit the podcast online at the link above.
Late Breaking news today! Now we have guidelines! Thanks to Dr. Rachel Rubin for coming on IG to do this live with me! AUA GSM Guidelines Learn more about your ad choices. Visit podcastchoices.com/adchoices
Featuring an interview with Dr William K Oh, including the following topics: Use of secondary hormonal agents for patients with metastatic hormone-sensitive prostate cancer (0:00) Data supporting the clinical activity of PARP inhibitors for metastatic castration-resistant prostate cancer (mCRPC) (11:10) Radiopharmaceuticals for the treatment of mCRPC (16:53) Available data on cabozantinib for mCRPC (24:38) Cabozantinib combinations for advanced renal cell carcinoma (RCC) (26:17) Subcutaneous nivolumab versus intravenous nivolumab for advanced RCC (30:00) Addition of nivolumab to tivozanib compared to tivozanib alone in advanced relapsed/refractory RCC previously treated with an immune checkpoint inhibitor (31:28) Long-term follow-up with belzutifan for relapsed/refractory advanced RCC (33:39) Major findings from the NIAGARA study of perioperative durvalumab for muscle-invasive bladder cancer (MIBC) (35:44) Data surrounding adjuvant immunotherapy for MIBC (38:07) Clinical development of TAR-200 for high-risk non-muscle-invasive bladder cancer (39:44) Updated analysis of EV-302 study of enfortumab vedotin in combination with pembrolizumab for previously untreated advanced urothelial cancer (UC) (41:06) Implementation of emerging data in the treatment landscape of UC (41:56) CME information and select publications
Dr William Oh from the Yale Cancer Center in New Haven, Connecticut, discusses recent updates on available and novel treatment strategies for genitourinary cancers. CME information and select publications here.
In this episode, Zev A. Wainberg, MD; Funda Meric-Bernstam, MD; Alexandra Leary, MD, PhD; and Catherine Fahey, MD, PhD, explore testing for HER2 alterations and the incidence of HER2-positive disease in the treatment of genitourinary, gastrointestinal, and gynecologic malignancies. HER2 Testing in Advanced Cancers: Recommendations for when and how to test for HER2 in advanced cancers and how these tests guide therapy selectionVariability in HER2 Expression Across Tumor Types: Insights into the heterogeneity of HER2 expression and amplification in different cancersChallenges in Standardizing HER2 Testing: The complexities of scoring and testing HER2 in different cancers and institutions, and the need for better harmonization of guidelines and approachesPresenters:Zev A. Wainberg, MDProfessor of Medicine and SurgeryCo-Director of GI OncologyDirector, Early Phase Clinical Research ProgramJonsson Comprehensive Cancer CenterUCLA School of MedicineLos Angeles, CaliforniaFunda Meric-Bernstam, MDChair, Department of Investigational Cancer TherapeuticsMedical Director, Institute for Personalized Cancer TherapyNellie B. Connally Chair in Breast CancerThe University of Texas MD Anderson Cancer CenterHouston, TexasAlexandra Leary, MD, PhDPresident, GINECO GroupCo-Director, Department of Medical OncologyMedical Oncologist GynecologyTeam Leader, Gynecologic Translational Research Lab, INSERM u981Institut Gustave RoussyVillejuif, FranceCatherine Fahey, MD, PhDAssistant ProfessorDivision of OncologyUniversity of North Carolina at Chapel HillChapel Hill, North CarolinaLink to full program:https://bit.ly/42iEDjVTo claim credit for listening to this episode, please visit the podcast online at the link above.
In this episode, I discuss with medical student, Sara Perelmuter: What is genitourinary syndrome of lactation (GSL)?Reasons why the postpartum vulvovaginal tissues resemble those of a menopausal womanSigns and symptoms of GSLPostpartum hormone changes How to talk to your provider about this What we need to know as providersDoes using topical estrogen harm the baby?Dose, frequency and length of time one may expect to use estrogenSara Perelmuter is a medical student at Weill Cornell in New York city and is already innovating the field of sexual medicine. She has over 7 scientifically peer reviewed publications and is currently the president of the Sexual Medicine Research Team. She is a passionate advocate for women's reproductive and sexual health and is on track to become an OB/GYN. Her prior research experience exposed her to the profound gap in research on women's sexual health and her clinical work exposed her to the prevalence of medical gaslighting and the dismissal of women's pain. Paired with her feminist values, this has motivated her to pursue a career dedicated to improving women's sexual health. Sara believes education, accessibility, and awareness are vital to break the barriers and help empower women to take control over their own bodies. Links mentioned in this episode: Genitourinary syndrome of lactation: a new perspective on postpartum and lactation-related genitourinary symptomsWebsite link of my Sexual Medicine Research Team with GSL infoSurvey Information SheetSurvey linkTHANK YOU TO THE EPISODE SPONSORSSRC Health: discount code and website: https://srchealth.com/?ref=Sto_l3PawmnH4. Discount Code: THEPELVICFLOORPROJECTThanks for joining me! Here is where you can find out how to work with me: www.pelvicfloorprojectspace.com/Support the show
Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern Medicine have established the Collaborative Advanced Reconstructive Evaluation (CARE) Clinic, which provides multidisciplinary care for children, adolescents and women with congenital anomalies and acquired diseases of the genitourinary tract. In this episode, two of the clinic's leaders, Drs. Julia Geynisman-Tan and Dr. Julia Grabowski, talk about the transformative surgical innovations they've developed and life-changing procedures and supportive care they offer to help women achieve functional vaginal anatomy, relief from pain, the ability to menstruate and more.
In this episode of The Life Transformer Show, Tara is chatting with Dr Sandar Hlaing about Genitourinary Syndrome. The reasons why it's not spoken about very often, and symptoms to look out for. Treatment and prevention for this syndrome and more. What You Will Learn In This Episode: What is Genitourinary Syndrome? Symptoms to watch out for. Why it's not spoken about. Treatment and prevention options. How To Contact Tara Hammett: tarahammett.com Facebook
I sit down with Dr William Oh, newly appointed Precision Medicine Director at Yale Cancer Center. Dr Oh is a Medical Oncologist who has focused mainly on Genitourinary cancers, so we of course talk about prostates. We discuss high risk populations and of course finding cancer early, knowing family histories and decision making about having surgery.
CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/insights-from-global-key-opinion-leaders-on-optimizing-patient-care-in-genitourinary-malignancies/29202/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/emerging-immunotherapy-combination-strategies-in-genitourinary-malignancies/29201/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/emerging-targeted-therapy-combination-strategies-in-genitourinary-malignancies/29200/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
Moderated by Sue Saville. With speakers: Susan Davis, James Simon, Tommaso Simoncini, Jean-Yves Reginster, Angelica Hirschberg. These podcasts were sponsored by Besins Healthcare.
Video: https://mehlmanmedical.com/hy-usmle-q-1127-genitourinary IG: https://www.instagram.com/mehlman_medical/ Telegram: https://mehlmanmedical.com/subscribe/ FB: https://www.facebook.com/mehlmanmedical Patreon: https://www.patreon.com/mehlmanmedical
Prof Enrique Grande, a medical oncologist from Madrid, Spain, is our guest on Oncology for the Inquisitive Mind this week. Enrique is not your average oncologist nor your average podcast guest with a fascinating back story, a varied career and the charisma and wisdom to match!Enrique has worked in all facets of oncology, including industry and is helping transform how patients access oncology care in Spain. He is the director of the Medical Oncology Program and Clinical Research Lead at the MD Anderson Centre Madrid. Prof Grande strongly focused on genitourinary and endocrine cancer research and was awarded his PhD in pharmacokinetic and pharmacodynamics study of tyrosine kinase inhibitors in liver metabolism.Listen on, and you will learn all there is to know about bladder cancer and the world of medical oncology.We explore the #NIAGARA trial, #EV302 and many other trials that are changing the face of bladder cancer!For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comOncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.Art courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.
In Oncology Unplugged, a podcast series from MedNews Week, host Chandler Park, MD, a medical oncologist at the Norton Cancer Institute in Louisville, Kentucky, talks through key updates in genitourinary cancer research from the 2024 ESMO Congress. In this episode, Dr Park highlights potentially practice-changing data in prostate, kidney, and bladder cancer; spotlights the potential clinical implications of findings with the intravesical therapy TAR-200 in patients with muscle-invasive bladder cancer (MIBC); and zooms in on data from the phase 3 NIAGARA trial (NCT03732677) of durvalumab (Imfinzi) plus gemcitabine and cisplatin in patients with MIBC.
ESMO 2024 was the year genitourinary cancer took front and centre stage with many exciting updates, trials, and tribulations. This week, OFTIM brings their greatest champion back to dive deep into the changes that will impact our patients and their families, the NCCN guidelines, and how we practice medicine. Unfortunately, the heavyweight champion boxer was unavailable, but we got the next best thing - Prof Anthony Joshua from St Vincent's Health and The Garvan Institute of Medical Research. This week, he discusses all things genitourinary cancer and gives a knockout performance.Enough boxing analogies - on with the show!Links to studies discussed in this episode (subscription may be required):PATCH+STAMPEDEARANOTESTAMPEDE (metformin Arm)PEACE-3SPLASHNIAGARAAMBASSADORTiNivo-2For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comOncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.Art courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Hosted on Acast. See acast.com/privacy for more information.
Send us a textIn today's episode, I sit down with Sara Perelmuter, a medical student and future OBGYN, who is already leading innovations in the field of sexual medicine. As president of the Sexual Medicine Research Team and with over seven peer-reviewed publications, Sara's latest work, "Genitourinary Syndrome of Lactation: A New Perspective on Postpartum and Lactation-Related Genitourinary Symptoms," introduces a new term encompassing genitourinary symptoms related to low estrogen during the postpartum and lactation periods.Sara's passion for women's health is deeply personal—her own struggle with pelvic pain during intercourse led to her diagnosis of hypertonic overactive pelvic floor muscle dysfunction. The medical gaslighting and dismissal she experienced, along with her feminist values and love for physiology, motivated her to pursue a career dedicated to improving women's sexual health. In this episode, Sara discusses the importance of education, accessibility, and awareness in empowering women to take control of their own bodies.We cover topics including:
OBGYN Briefs - Managing Genitourinary Syndrome of Menopause Frequent UTIs and vaginal atrophy/dryness are common signs of genitourinary syndrome of menopause (GSM). In this Brief, Dr. Rachel Rubin discusses the management of GSM and why estrogen is so vital to these tissues. They address the lack of information and awareness about GSM among urologists and gynecologists while emphasizing its impact on the urinary and genital symptoms experienced by menopausal women. Dr. Rubin details how GSM is not just a matter of vaginal atrophy but involves broader symptoms like urinary tract infections and bladder issues. The doctors also discuss a range of treatment options available, including local vaginal supplementation products like estradiol creams and DHEA suppositories, and their benefits for urinary health. TIMESTAMPS 00:00 - Introduction 00:20 - Understanding Genitourinary Syndrome of Menopause (GSM) 01:42 - Symptoms and Implications of GSM 03:00 - Vaginal Supplementation Products 05:09 - DHEA and SERM Therapy 08:44 - Estrogen and Vaginal Health CHECK OUT THE FULL EPISODE OBGYN Ep. 33 - Genitourinary Syndrome of Menopause (GSM): Improving a DRY Topic https://www.backtable.com/shows/obgyn/podcasts/33/genitourinary-syndrome-of-menopause-gsm-improving-a-dry-topic
Dr. Rachel S. Rubin is a board certified urologist with fellowship training in sexual medicine. She is an assistant clinical professor in urology at Georgetown University and owns her own practice in Washington DC. Dr. Rubin provides comprehensive care to all genders. She treats issues such as pelvic pain, menopause, erectile dysfunction, and low libido. Dr. Rubin is the director at large and former education chair for the International Society for the Study of Women's Sexual Health (ISSWSH) and an associate editor for the journal Sexual Medicine Reviews. Her work has been featured in the NYT, NPR and PBS. She was named a Washingtonian Top Doctor in 2019-2023.She has co-authored several publications on Genitourinary Syndrome ofMenopause (GSM) including:Houston CG, Azar WS, Huang SS, Rubin R, Dorris CS, Sussman RD. A Cost Savings Analysis of Topical Estrogen Therapy in Urinary Tract Infection Prevention Among Postmenopausal Women. Urology Practice. 2024 Mar 1; 11(2):257-266.https://doi.org/10.1097/UPJ.0000000000000513Wasserman MC and Rubin RS. Urologic view in the management of genitourinary syndrome of menopause. Climacteric. 2023 Apr 27;1-7. doi: 10.1080/13697137.2023.2202811. Epub aheadof print. PMID: 37104711.To learn more about Dr. Rachel Rubin MD, check out: https://www.rachelrubinmd.com/Or follow her on Instagram @drrachelrubinTo Follow US check out: Heather- www.theshowcenter.comJackie- https://www.mymonarchhealthco.comThe podcast- @justaskhiveHeather- @showcenterdrqJackie- @jackiep_gynnpThe course is live and available at:the-hive8.teachable.com
Video of this clip: https://mehlmanmedical.com/hy-usmle-q-1058-genitourinary Main website: https://mehlmanmedical.com/ IG: https://www.instagram.com/mehlman_medical/ Telegram private group: https://mehlmanmedical.com/subscribe/ FB: https://www.facebook.com/mehlmanmedical Patreon: https://www.patreon.com/mehlmanmedical
Dr. Ardelle Piper is a Royal College Certified OB/GYN, and focuses her gynecology practice on midlife women's health. She is known as a leader and pioneer in telemedicine, and provides menopause assessments over videoconference to women across Ontario since 2020. As a subject matter expert, Dr. Piper is frequently called upon as keynote speaker to provide menopause education to medical colleagues and the community, and collaborates with other social media educators. She advocates for improved appreciation of menopause in organizations and the general public, and health education in workplace wellness programs.Dr. Piper completed a BSc(H) in Cell and Developmental Biology, then achieved her medical degree (MD) at the University of British Columbia in Vancouver in 2006. Appreciating her passion for women's health and education, she pursued an Obstetrics & Gynecology residency and a MEd in Saskatchewan, with a thesis on School Based Sexual Health Education. Through this she enjoyed leadership opportunities as a provincial representative with the Canadian Association of Interns and Residents (CAIR) and was Chair of the Junior Member Committee of the Society of Obstetricians and Gynecologists of Canada (SOGC). During her obstetrical training and career, Dr. Piper welcomed into the world over 1500 babies, and co-chaired the Management of Postpartum Hemorrhage Simulation Workshops at the Federation of International Gynecologist and Obstetricians (FIGO) World Congress in Vancouver (2015) and Brazil (2018).She realized her interest in education, advocacy, and women's health aligned perfectly with the field of Menopause, and she achieved a final year of sub-specialty training in Midlife Women's Health at The Shirley E. Greenberg Women's Health Centre in Ottawa in 2014, and has maintained NAMS Certified Menopause Practitioner status since (NCMP has now been renamed MSCP). Her gynecology practice provides subspeciality consultation focused on menopause education, hormone therapy, sexual function, post-cancer thrivership, and preventive health promotion. With the pandemic, she has pioneered providing menopause assessments through telemedicine across Ontario. As a subject matter expert, she frequently provides menopause education to not only her physician colleagues, but also in public forums and workplaces, advocating for improved midlife women's health care.https://bywardfht.ca/our-services/menopause-clinic/https://www.instagram.com/dr.a.piper/?hl=enThank you so much for listening! I use fitness and movement to help women prevent and overcome pelvic floor challenges like incontinence and organ prolapse. There is help for women in all life stages! Every Woman Needs A Vagina Coach! Please make sure to LEAVE A REVIEW and SUBSCRIBE to the show for the best fitness and wellness advice south of your belly button. *******************I recommend checking out my comprehensive pelvic health education and fitness programs on my Buff Muff AppYou can also join my next 28 Day Buff Muff Challenge https://www.vaginacoach.com/buffmuffIf you are feeling social you can connect with me… On Facebook https://www.facebook.com/VagCoachOn Instagram https://www.instagram.com/vaginacoach/On Twitter https://twitter.com/VaginaCoachOn The Web www.vaginacoach.comGet your Feel Amazing Vaginal Moisturizer Here
“It was nothing to worry about,” Andrew was repeatedly told, when he visitedurgent care twice for pain in his pelvis area. But the discomfort wouldn't go away, so he met with his primary care physician who referred him to a urologist for an ultrasound. The scans led to a testicular cancer diagnosis in early 2023. It was caught early enough, and he was told there was a good prognosis. The cancer had only spread very lightly to his lymph nodes. Adam works as the director of data analytics for a pharmaceutical company. Heloves vacationing with his family, watching his children play their sports (soccer for his son Jacob and gymnastics for his daughter Julia) and caring for his 2004 BMW. He hopes to help normalize conversations around testicular cancer for other men so they can overcome stigmas and shame around it. Today, he and his wife Kara arecelebrating their wedding anniversary. Dr. Atish Choudhury is a medical oncologist and clinical/translational investigatorwithin the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, and currently serves as Chair of the Gelb Center for Translational Research. He also serves as an Assistant Professor of Medicine at Harvard Medical School. His research interests include investigation of genetic and epigenetic biomarkers from circulating free DNA from patients with metastatic cancer, biomarker studies from other banked human specimens from patients participating in clinical trials, and clinical investigation in novel therapeutics for genitourinary malignancies. According to the American Cancer Society, testicular cancer is not common. About 1 of every 250 males will develop testicular cancer at some point during their lifetime. The American Cancer Society's estimate for testicular cancer in the United States for 2024 is about 9,760 new cases of testicular cancer diagnosed. The average age of males when first diagnosed with testicular cancer is about 33. This is largely a disease of young and middle-aged men, but about 6% of cases occur in children and teens, and about 8% occur in men older than 55.
Description: Dr. Katie Epstein summaries the article “Troubleshooting Tips for Diagnosing Complex Fetal Genitourinary Malformations” published in RadioGraphics Troubleshooting Tips for Diagnosing Complex Fetal Genitourinary Malformations. Griffith et al. RadioGraphics 2024; 44(1):e230084.
A patient with multiple sclerosis experiences bladder dyssynergia during micturition. Which of the following descriptions BEST matches this condition? Find it all out in the podcast! Be prepared for the NPTE so that you can pass with flying colors! Check out www.ptfinalexam.com/podcast for more information and to stay up-to-date with our latest courses and projects.
Which of the following groups of signs and symptoms are MOST commonly present in a patient with dyssynergic bladder? Find it all out in the podcast! Be prepared for the NPTE so that you can pass with flying colors! Check out www.ptfinalexam.com/podcast for more information and to stay up-to-date with our latest courses and projects.
© 2020-2025 Ivy Podcast Discovery LLC
